Filing Flows › Abeona Therapeutics (ABEO) › Q1 2026 › vs Q4 2025
Abeona Therapeutics (ABEO) Q1 2026 vs Q4 2025 (quarter over quarter)
Abeona Therapeutics's revenue rose $3.3M (+61%) from $5.4M in Q4 2025 to $8.7M in Q1 2026.
Abeona Therapeutics, Q1 2026: revenue $8.7M, operating margin -264.1%, net loss $17.1M, operating cash flow −$19.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.7M | $5.4M | $3.3M | +61% |
| Other income, net | $6.0M | $2.2M | $3.7M | +167% |
| Net loss | $17.1M | $20.5M | −$3.4M | -17% |
| Costs & expenses | $31.8M | $28.3M | $3.4M | +12% |
| Operating costs | $31.8M | $28.3M | $3.4M | +12% |
| Income tax | $2K | −$215K | $217K | — |
| Cost of revenue | $2.7M | $1.0M | $1.7M | +158% |
| Research & development | $9.6M | $6.7M | $2.8M | +42% |
| SG&A | $19.5M | $18.8M | $720K | +4% |
| Operating cash sources | $23.5M | $21.4M | $2.1M | +10% |
| Depreciation & amortization | $690K | $863K | −$173K | -20% |
| Share-based compensation | $3.0M | $2.6M | $398K | +16% |
| Cash used in operations | $19.8M | $18.0M | $1.9M | +10% |
| Net loss absorbed | $17.1M | $20.5M | −$3.4M | -17% |
| Working capital & other | $6.4M | $915K | $5.5M | +597% |
Questions
How much did Abeona Therapeutics's revenue grow quarter over quarter in Q1 2026?
Abeona Therapeutics's revenue rose $3.3M (+61%) from $5.4M in Q4 2025 to $8.7M in Q1 2026.